Graft Polymer (UK) PLC ( (GB:SVNS) ) just unveiled an announcement.
Solvonis Therapeutics plc has provided an update on the R&D progress of Awakn Life Sciences Corp., which it plans to acquire. Awakn’s research includes three main programs: AWKN-001, a combination therapy for severe alcohol use disorder currently in a Phase 3 trial in the UK; AWKN-002, an esketamine oral thin film for AUD in the US, which is moving towards a Phase 2b trial; and AWKN-SND-14, a pre-clinical investigation for PTSD. These developments could strengthen Solvonis’ position in the biotechnology industry, potentially offering innovative treatments for AUD and PTSD, addressing significant unmet medical needs.
More about Graft Polymer (UK) PLC
Solvonis Therapeutics plc is an innovative biotechnology company focused on developing intellectual property related to the treatment of mental health and substance use disorders. It co-develops therapeutics for mental health disorders with an initial focus on trauma-related mental health conditions such as PTSD. Solvonis aims to improve outcomes for individuals suffering from mental health disorders.
YTD Price Performance: -7.50%
Average Trading Volume: 26,908,424
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £4.25M
See more insights into SVNS stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com